0.00Open6.90Pre Close0 Volume0 Open Interest3.50Strike Price0.00Turnover0.00%IV10.76%PremiumDec 13, 2024Expiry Date5.89Intrinsic Value100Multiplier-2DDays to Expiry1.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.36Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Altimmune Stock Discussion
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet